Shen D C, Davidson M B, Kuo S W, Sheu W H
Department of Medicine, Tri-Service General Hospital, Taipei, Taiwan, Republic of China.
J Clin Endocrinol Metab. 1988 Mar;66(3):565-9. doi: 10.1210/jcem-66-3-565.
Eight hyperthyroid and eight normal subjects underwent 2-h oral glucose tolerance tests (OGTT) and euglycemic clamp studies to assess the presence of peripheral and hepatic insulin antagonism in hyperthyroidism. Although the mean total glucose area during the OGTT was similar in the hyperthyroid patients and normal subjects [16.4 +/- 0.8 (+/- SE) vs. 15.8 +/- 0.7 mmol/L.h], the mean insulin area was significantly elevated in the hyperthyroid group (1413 +/- 136 vs. 1004 +/- 122 pmol/L.h; P less than 0.05). Basal hepatic glucose production was measured during the second hour of a primed [3-3H]glucose infusion. A two-insulin dose euglycemic clamp study with [3-3H]glucose and somatostatin (500 micrograms/h) was carried out during the next 6 h. The insulin infusion rate was 0.05 mU/kg.min during the third, fourth, and fifth hours and 0.60 mU/kg.min during the sixth, seventh, and eighth hours. Hepatic glucose production and glucose utilization were measured during the final 0.5 h of each clamp period. Serum C-peptide concentrations were measured in the initial sample and in the last sample of each clamp period. The mean equilibrium serum insulin concentrations were similar in both groups during the final 0.5 h of the low (90 +/- 8 vs. 79 +/- 6 pmol/L) and high (367 +/- 11 vs. 367 +/- 15 pmol/L) insulin infusion rates. Basal serum C-peptide levels were significantly increased in the hyperthyroid patients (596 +/- 17 vs. 487 +/- 43 pmol/L; P less than 0.05) but were suppressed equally in both groups at the end of both clamp periods. The MCRs of insulin were similar in the hyperthyroid and normal subjects during the low (6.7 +/- 1.1 vs. 5.6 +/- 0.5 mL/kg.min) and high (11.9 +/- 0.4 vs. 12.1 +/- 0.5 mL/kg.mm) insulin infusion rates. Glucose production was significantly increased in the hyperthyroid patients during the basal state (17.6 +/- 0.9 vs. 11.5 +/- 0.5 mumol/kg.min; P less than 0.001) and remained elevated during the final 0.5 h of the low (12.1 +/- 1.1 vs. 5.9 +/- 1.7; P less than 0.01) and high (3.2 +/- 1.2 vs. 0.5 +/- 0.3; P less than 0.05) insulin infusion rates. Peripheral insulin action, assessed by Bergman's sensitivity index, was significantly decreased in the hyperthyroid patients (7.4 +/- 2.2 vs. 15.6 +/- 2.1 L/kg min-1/pmol/L; P less than 0.02). In conclusion, hyperthyroidism is characterized by 1) hyperinsulinemia after oral glucose loading, 2) increased basal hepatic glucose production, 3) impairment of insulin-mediated suppression of hepatic glucose production, and 4) antagonism to insulin-stimulated peripheral glucose utilization.
八名甲状腺功能亢进患者和八名正常受试者接受了2小时口服葡萄糖耐量试验(OGTT)和正常血糖钳夹研究,以评估甲状腺功能亢进症患者外周和肝脏胰岛素抵抗的情况。尽管甲状腺功能亢进症患者和正常受试者在OGTT期间的平均总葡萄糖面积相似[16.4±0.8(±标准误)对15.8±0.7 mmol/L·h],但甲状腺功能亢进症组的平均胰岛素面积显著升高(1413±136对1004±122 pmol/L·h;P<0.05)。在给予[3-3H]葡萄糖负荷后的第2小时测量基础肝脏葡萄糖生成。接下来的6小时内进行了一项使用[3-3H]葡萄糖和生长抑素(500微克/小时)的双胰岛素剂量正常血糖钳夹研究。在第3、4和5小时胰岛素输注速率为0.05 mU/kg·min,在第6、7和8小时为0.60 mU/kg·min。在每个钳夹期的最后0.5小时测量肝脏葡萄糖生成和葡萄糖利用情况。在每个钳夹期的初始样本和最后样本中测量血清C肽浓度。在低胰岛素输注速率(90±8对79±6 pmol/L)和高胰岛素输注速率(367±11对367±15 pmol/L)的最后0.5小时,两组的平均平衡血清胰岛素浓度相似。甲状腺功能亢进症患者的基础血清C肽水平显著升高(596±17对487±43 pmol/L;P<0.05),但在两个钳夹期结束时两组均受到同等程度的抑制。在低胰岛素输注速率(6.7±1.1对5.6±0.5 mL/kg·min)和高胰岛素输注速率(11.9±0.4对12.1±0.5 mL/kg·min)时,甲状腺功能亢进症患者和正常受试者的胰岛素代谢清除率相似。在基础状态下,甲状腺功能亢进症患者的葡萄糖生成显著增加(17.6±0.9对11.5±0.5 μmol/kg·min;P<0.001),并且在低胰岛素输注速率(12.1±1.1对5.9±1.7;P<0.01)和高胰岛素输注速率(3.2±1.2对0.5±0.3;P<0.05)的最后0.5小时仍保持升高。通过伯格曼敏感性指数评估的外周胰岛素作用在甲状腺功能亢进症患者中显著降低(7.4±2.2对15.6±2.1 L/kg·min-1/pmol/L;P<0.02)。总之,甲状腺功能亢进症的特征为:1)口服葡萄糖负荷后高胰岛素血症;2)基础肝脏葡萄糖生成增加;3)胰岛素介导的肝脏葡萄糖生成抑制受损;4)对胰岛素刺激的外周葡萄糖利用产生抵抗。